Business Context and Reporting Period
This Form 8-K Current Report was filed by Apyx Medical Corporation on February 6, 2025, covering events occurring on January 31, 2025. The filing primarily addresses Item 5.02 regarding the formalization of an employment agreement with a newly appointed executive officer.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. This report focuses exclusively on executive compensation terms rather than financial performance results.
Material Changes
The material change reported is the execution of an Employment Agreement with Shawn Roman, effective January 28, 2025, following his prior appointment as Chief Operating Officer. Key compensation terms include:
- Base Salary: $305,760.52 annually.
- Annual Bonus: Target bonus of not less than 50% of the Base Salary, contingent on achieving specific objectives.
- Equity: Eligibility to participate in the Company's equity-based incentive plans, with awards determined by the Compensation Committee.
- Termination Benefits: Provision for earned but unpaid amounts and other benefits upon termination, subject to the execution of a Release and non-breaching of Restrictive Covenants.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, financial outlook, or discussion of general business risks. The only contingencies mentioned relate to the conditions precedent for receiving termination benefits under the new employment agreement.
Investor Verification Checklist
- Verify the full text of the Employment Agreement attached as Exhibit 10.1 for specific performance metrics tied to the bonus plan.
- Confirm the specific terms of the equity awards and vesting schedules, which are determined by the Compensation Committee.
- Review the definition of "Restrictive Covenants" and "Release" to understand the conditions for severance eligibility.
- Check subsequent filings for any updates to the Company's cash position required to fund the new executive compensation.